It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

Latest Publications:

As of October 29, 2021, a total of 2,9471 patients received siponimod in clinical trials including open-label extensions and, as of March 25, 2022, more than 15,000 patients in the postmarketing setting received siponimod2**

Home page figure_v2
**Postmarketing exposure is estimated from the global sales data
Click here to request siponimod local Prescribing Information
Click here to request siponimod local RMP educational material

Report an adverse event

Border image
Abbreviations
COVID-19, corona virus disease-19; HCP, health-care professional
References
1. Data on File, cutoff date 29-October-2021, Novartis Pharma AG.
2. Data on File, PSUR, cutoff date 25-March-2022, Novartis Pharma AG.
* Indication varies in different countries. Current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of siponimod in the individual country.

The Pregnancy outcome Intensive Monitoring (PRIM) program is based on enhanced pharmacovigilance of the Novartis spontaneous reporting system. PRIM is an adverse event outcomes intensive monitoring program to collect information (targeted follow-up checklists) about pregnancy in patients exposed to siponimod immediately before or during pregnancy and infant outcomes 12 months after delivery.